The Swiss pharmaceutical Helsinn Group, a leading player in the cancer
supportive care arena, announced today that DARA BioSciences, Inc. DARA, a U.S.
specialty pharmaceutical company focused on oncology and oncology supportive
care products, has launched Gelclair ^® into the U.S. market. Gelclair ^® is
manufactured by the Helsinn Group and is an FDA-cleared product indicated for
the treatment of oral mucositis.
Oral mucositis is a painful inflammation and ulceration of the surface of the
mouth and throat, which can result from a variety of cancer treatments.
Gelclair ^® provides oral mucositis patients rapid and effective relief of
pain. Oral mucositis is common in cancer patients undergoing chemotherapy or
radiation therapy and occurs when the protective oral mucosa is denuded,
potentially resulting in pain, infection, weight loss, decreased quality of
life, treatment delay and increased economic costs.
Helsinn Group Chief Executive Officer, Riccardo Braglia, said, "We are pleased
that DARA is launching Gelclair ^® in the United States, and importantly, that
U.S. patients will again be able to benefit from this treatment. We believe
this is an important milestone in building the long-term relationship between
our companies. It will also add the most important market worldwide to the
other 30 where Gelclair ^® is already marketed in Europe, Latin America and
Asia."
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in